Weekly Investment Analysts’ Ratings Changes for Stryker (SYK)

A number of research firms have changed their ratings and price targets for Stryker (NYSE: SYK):

  • 7/29/2019 – Stryker was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $225.00 price target on the stock. According to Zacks, “Stryker exited the second quarter of 2019 on a solid note, with earnings and revenues surpassing the consensus mark. The company continues to gain from its core MedSurg unit which put up a strong show in the reported quarter. Additionally, strength in flagship Mako platform continues to favor the company. Moreover, sustained solid demand for Neurotech products drove the core Neurotechnology & Spine unit in the quarter under review. Robust international growth also buoys optimism. Expansion in operating margin is a positive while strong outlook for 2019 is indicative of bright prospects. However, contraction in gross margin raises concern. Pricing pressure also continues to plague Stryker. Stiff competition in the MedTech space remains a headwind. The stock looks overvalued at the moment.”
  • 7/29/2019 – Stryker had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $228.00 price target on the stock.
  • 7/26/2019 – Stryker had its price target raised by analysts at Piper Jaffray Companies from $205.00 to $240.00. They now have an “overweight” rating on the stock.
  • 7/26/2019 – Stryker had its price target raised by analysts at Robert W. Baird from $206.00 to $239.00. They now have an “outperform” rating on the stock.
  • 7/26/2019 – Stryker had its price target raised by analysts at Credit Suisse Group AG from $232.00 to $237.00. They now have an “outperform” rating on the stock.
  • 7/26/2019 – Stryker had its price target raised by analysts at Cantor Fitzgerald from $190.00 to $230.00. They now have a “neutral” rating on the stock.
  • 7/26/2019 – Stryker was given a new $216.00 price target on by analysts at BMO Capital Markets. They now have a “hold” rating on the stock.
  • 7/26/2019 – Stryker was given a new $240.00 price target on by analysts at Raymond James. They now have a “buy” rating on the stock.
  • 7/26/2019 – Stryker was given a new $220.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 7/26/2019 – Stryker was given a new $226.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 7/26/2019 – Stryker had its price target raised by analysts at Canaccord Genuity from $195.00 to $233.00. They now have a “buy” rating on the stock.
  • 7/16/2019 – Stryker had its price target raised by analysts at Morgan Stanley from $218.00 to $230.00. They now have an “overweight” rating on the stock.
  • 7/15/2019 – Stryker had its price target raised by analysts at BTIG Research to $219.00. They now have a “positive” rating on the stock.
  • 7/11/2019 – Stryker had its price target raised by analysts at Credit Suisse Group AG from $200.00 to $232.00. They now have an “outperform” rating on the stock.
  • 7/10/2019 – Stryker had its “outperform” rating reaffirmed by analysts at Svb Leerink Llc.
  • 7/2/2019 – Stryker had its price target raised by analysts at Wells Fargo & Co from $219.00 to $228.00. They now have an “outperform” rating on the stock.
  • 6/11/2019 – Stryker was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $206.00 price target on the stock. According to Zacks, “Stryker continues to gain from its core MedSurg unit which put up a strong show in the reported quarter. Additionally, strength in flagship Mako platform continues to favor the company. Moreover, its K2M acquisition drove the core Neurotechnology & Spine unit in the quarter under review. Solid international growth also buoys optimism. Expansion in operating margin is a positive while strong outlook for 2019 is indicative of bright prospects. Stryker has outperformed the industry in a year’s time. Stryker exited the first quarter of 2019 on a solid note, with earnings surpassing the consensus mark and revenues increasing on a year-over-year basis. However, contraction in gross margin raises concern. Pricing pressure also continues to plague Stryker. Stiff competition in the MedTech space remains a headwind.”

Shares of SYK traded down $1.30 on Friday, reaching $211.62. 1,158,800 shares of the stock traded hands, compared to its average volume of 1,254,530. The firm has a market cap of $79.91 billion, a price-to-earnings ratio of 28.95, a price-to-earnings-growth ratio of 2.59 and a beta of 0.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.26 and a current ratio of 2.07. Stryker Co. has a 12 month low of $144.75 and a 12 month high of $222.59. The stock’s 50-day moving average is $206.68.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 25th. The medical technology company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.93 by $0.05. The business had revenue of $3.65 billion for the quarter, compared to analysts’ expectations of $3.60 billion. Stryker had a return on equity of 25.98% and a net margin of 24.99%. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.76 earnings per share. As a group, equities research analysts anticipate that Stryker Co. will post 8.2 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Friday, September 27th. Stryker’s dividend payout ratio is presently 28.45%.

In other Stryker news, CFO Glenn S. Boehnlein sold 2,700 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $188.21, for a total value of $508,167.00. Following the sale, the chief financial officer now directly owns 23,333 shares in the company, valued at $4,391,503.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Timothy J. Scannell sold 4,666 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $186.71, for a total value of $871,188.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,398 shares of company stock worth $4,221,459. 7.20% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in the business. Gamco Investors INC. ET AL bought a new stake in Stryker in the second quarter valued at $658,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Stryker by 13.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 33,014 shares of the medical technology company’s stock worth $6,787,000 after purchasing an additional 4,016 shares in the last quarter. Rudd International Inc. acquired a new position in Stryker in the second quarter worth $3,900,000. Hillsdale Investment Management Inc. acquired a new position in Stryker in the second quarter worth $512,000. Finally, Holderness Investments Co. boosted its stake in Stryker by 18.5% in the second quarter. Holderness Investments Co. now owns 4,424 shares of the medical technology company’s stock worth $909,000 after purchasing an additional 691 shares in the last quarter. Hedge funds and other institutional investors own 73.53% of the company’s stock.

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: Call Option

Receive News & Ratings for Stryker Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co and related companies with MarketBeat.com's FREE daily email newsletter.